In this diverse cohort, a positive ctDNA TF at baseline was associated with worse outcomes in mHSPC and may potentially complement current further risk stratification tools.
Abstract
Purpose
There are few established prognostic biomarkers in metastatic hormone-sensitive prostate cancer (mHSPC). Disease volume and timing of metastases are prognostic and predictive factors but may be inadequate due to heterogeneity. Circulating tumor DNA (ctDNA) provides both circulating volume (tumor fraction [TF]) and genomic data. There are limited data on ctDNA in mHSPC.
Methods
This was a multicenter, prospective study of ctDNA testing in mHSPC. Presented here are the results before androgen-deprivation therapy initiation. The primary objective was to evaluate the association between TF and overall survival (OS) and time to mCRPC (TTCRPC). Secondary analyses included evaluating outcomes in subgroups of interest and key genomic subtypes.
Results
Between 2018 and 2024, 85 patients were enrolled, of whom 72 (25% Black) had evaluable baseline ctDNA samples and are included herein. Baseline TF was positive in 46 patients (64%). Compared with patients with negative ctDNA TF, most patients with positive ctDNA TF had de novo (87% v 39%, P < .001) and high-volume disease (80% v 46%, P = .01). At a median follow-up of 20.8 months, median OS was not reached (NR) with those with negative ctDNA TF and 33 months with positive ctDNA TF (hazard ratio [HR], 3.33 [95% CI, 1.1 to 9.9]; P = .03). However, a negative TF at baseline was associated with an undetectable 7-month prostate-specific antigen, a validated OS surrogate. Median TTCRPC was NR versus 13 months (HR, 3.43 [95% CI, 1.5 to 7.9]; P = .004). ctDNA TF was also potentially prognostic in high-volume disease and those who received doublet therapy.
Conclusion
In this diverse cohort, a positive ctDNA TF at baseline was associated with worse outcomes in mHSPC and may potentially complement current further risk stratification tools.
BACKGROUND
Multiple studies have demonstrated that circulating tumor DNA (ctDNA), a component of liquid biopsy, exhibits strong performance in predicting prognosis across various types of tumors. However, its role in predicting prognosis among gastric cancer patients undergoing treatment remains inconclusive. Therefore...
Yu-Ze Liu, Yan-Li Liu, Dan Liu et al.· European Journal of Surgical...· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis with few validated biomarkers for disease monitoring. Circulating tumor DNA (ctDNA) is a promising liquid biopsy-based biomarker, but its clinical utility remains incompletely defined. While most available data focus on early-stage disease, we eva...
Daiane Hemerich Brennan, Nina Kozlova, Gonzalo Lopez et al.· Cancer Research· 0 citations
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) carries high mortality despite neoadjuvant chemotherapy (NAC) and surgical resection, creating an urgent need for prognostic biomarkers to guide treatment. We aimed to determine whether circulating tumor DNA (ctDNA) detected by next-generation sequencing (NGS) predicts...
Krishay Sridalla, Dominic J. Vitello, Madison Cox et al.· Annals of Surgical Oncology· 0 citations
Background Stage II colon cancer is clinically heterogeneous. Current clinicopathologic risk factors cannot accurately identify patients with residual disease after curative resection. Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for the detection of minimal residual disease (MRD), defined as micr...
Er-Hua Yang, Xue-Feng Wang, Jia-Jing Zhang et al.· Frontiers in Oncology· 0 citations
BACKGROUND
The impact of circulating tumour DNA (ctDNA) detection, which informs minimal residual disease (MRD) after curative treatment, remains debated especially for stage IV patients.
OBJECTIVE
The study objectives were to evaluate the prognostic role of MRD and to estimate lead time (LT) at different timepoints...
G. Maddalena, K. Aziz, Ryan Sun et al.· Gut· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.